# Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

> **NCT04405622** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 21 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Chemotherapy Effect
- Immunotherapy

## Interventions

- **DRUG:** Toripalimab plus gemcitabine

## Key facts

- **NCT ID:** NCT04405622
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-30
- **Primary completion:** 2023-03
- **Final completion:** 2023-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405622, "Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04405622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*